Bli medlem
Bli medlem

Du är här


Oncology Venture: Oncology Ventures DRP for identification of patients who benefit from 5-FU treatment - data published in PLOS ONE

Hoersholm, Denmark; May 12th, 2016 - Oncology Venture Sweden AB
(OV:ST) announces that positive data on the in-licensed technology
from Medical Prognosis Institute, the Drug Response Predictor (DRP),
has been published in the scientific journal PLOS ONE with the title:
"Cell line derived 5-FU and irinotecan drug-sensitivity profiles
evaluated in adjuvant colon cancer trial data". Data from a
prospective randomized clinical trial was analyzed with the unique
DRP™ tool. The DRP for 5-FU could identify which patients benefitted
from treatment with 5-FU. When looking at overall survival the
patients with the most positive predictor have twice the survival
rate of the patients with poor prediction.

"The publication in PLOS ONE is an important mile stone documenting
the solid data on the Drug Response Predictor - DRP™ - both
demonstrated in prospective, retrospective and blinded clinical
studies - this time in collaboration with an international well known
academic group. All calculations were done by external researchers
that are independent from MPI" said Adjunct professor Peter Buhl
Jensen, M.D., DMSc and CEO of Oncology Venture.

"5-FU is one of the most important chemotherapeutics which is widely
used around the world - and yet there is until now no biomarker in
clinic to tell whether a patient is likely to benefit from the
treatment or not. I believe that the specific DRP™ has potential to
increase the survival rate for certain cancer patients," Peter Buhl
Jensen further added.

In this international collaboration between MPI and two independent
public science groups gene expression from tumors from 636 stage III
colon cancer patients was evaluated. Conclusion were that "The 5-FU
predictor was prognostic in stage III patients in PETACC-3 but not in
stage II patients with no adjuvant therapy. This suggests a potential
predictive ability of the 5-FU sensitivity profile to identify colon
cancer patients who may benefit from 5-FU."

Selected data from the publication shows that the 5-FU specific DRP™
in PETACC-3 showed a statistically significant association with
relapse free survival (RFS) (hazard ratio (HR) = 0.54 (0.41-0.71),
p<1e-05) and overall survival (HR = 0.47 (0.34-0.63), p<1e-06). The
effect of the 5-FU profile remained significant in a multivariable
model, adjusting for several relevant clinical and tissue specific

About the Drug Response Predictor -DRP™ - screening tool

Oncology Venture uses the MPI DRP™ to select those patients that by
the gene signature in their cancer is found to have a high likelihood
of response to the drug. The goal is to develop the drug for the
right patients and by screening patients before treatment the
response rate can be significantly increased.

This DRP™ method builds on the comparison of sensitive vs. resistant
human cancer cell lines including genomic information from cell lines
combined with clinical tumor biology and clinical correlates in a
systems biology network. The DRP™ based on microRNA is used on
certain products where the DRP™ based on messenger RNA is more
broadly useable and more validated.

Please find the full publication on: PLOS ONE

For further information, please contact

Ulla Hald Buhl, COO and Chief IR & or Peter Buhl Jensen, CEOMobile: +45 21
CommunicationsMobile: +45 2170 60 89 22E-mail:

About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development
of anti-cancer drugs via its wholly owned Danish subsidiary Oncology
Venture ApS. Oncology Venture has a license to use Drug Response
Prediction - DRP™ - in order to significantly increase the
probability of success in clinical trials. DRP™ has proven its
ability to provide a statistically significant prediction of clinical
outcomes from drug treatment in cancer patients in 29 of the 37
clinical studies that were examined. The Company uses a model that
alters the odds in comparison with traditional pharmaceutical
development. Instead of treating all patients with a particular type
of cancer, patients are screened first and only those who are most
likely to respond to the treatment will be treated. Via a more
well-defined patient group, the risk and costs are reduced while the
development process becomes more efficient.

The current product portfolio: LiPlaCis an intelligent liposomal
formulation of cisplatin for Breast Cancer, Irofulven developed from
a fungus for prostate cancer and APO010 - an immuno- oncology product
for Multiple Myeloma.


Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.